New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Merck & Co., Inc.

MRK

Healthcare Drug Manufacturers General

Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024.

Revenue
+4.68%
EPS
−12.1%
Free cash flow
−19.3%
Total debt
+24.3%

Quarter to September 2026, against a year earlier

134.50 1.76 +1.33%
Market cap
$328.6B
P/E
137×
Fwd P/E FY26e
105×
Dividend yield
2.56%
F-score
4/9
ROIC
4.56%
Net debt / EBITDA
1.2×
Payout ratio
3.5×

Merck & Co., Inc. 10-Q filed Nov 5, 2025

Fiscal Q3 2025 · Period ended Sep 30, 2025 · Filed · accepted 4:08 PM ET · Document on sec.gov · Filing index

What changed

Part II, Item 1A, Risk Factors, against the 10-Q filed Aug 5, 2025: no comparison — the Item was not found